---
title: "IMM: First-in-class immunotherapies efti and IMP761 advance in oncology and autoimmunity"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296543630.md"
description: "A diversified immunotherapy pipeline is advancing in oncology and autoimmune diseases, led by first-in-class assets efti and IMP761. Efti shows strong efficacy in NSCLC and HNSCC, though a Phase III NSCLC trial was discontinued. IMP761 demonstrated safety and pharmacodynamic activity in Phase I, targeting large autoimmune markets.Original document: Immutep Ltd [IMM] Slides Release — Aug. 20 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-08-20T22:54:34.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296543630.md)
  - [en](https://longbridge.com/en/news/296543630.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296543630.md)
generator: "portal-rs"
---

# IMM: First-in-class immunotherapies efti and IMP761 advance in oncology and autoimmunity

A diversified immunotherapy pipeline is advancing in oncology and autoimmune diseases, led by first-in-class assets efti and IMP761. Efti shows strong efficacy in NSCLC and HNSCC, though a Phase III NSCLC trial was discontinued. IMP761 demonstrated safety and pharmacodynamic activity in Phase I, targeting large autoimmune markets.

Original document: Immutep Ltd \[IMM\] Slides Release — Aug. 20 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [IMMP.US](https://longbridge.com/en/quote/IMMP.US.md)
- [IMM.AU](https://longbridge.com/en/quote/IMM.AU.md)

## Related News & Research

- [IMM: Discontinuation of TACTI-004 caused impairment, but strong cash and positive clinical data support future prospects](https://longbridge.com/en/news/297439554.md)
- [Sam Altman says AI needs to do more than cure cancer to win over skeptics](https://longbridge.com/en/news/298040546.md)
- [Corcept names Roberto Vieira as President, Oncology in initial beneficial ownership filing](https://longbridge.com/en/news/297971867.md)
- [Caris Life Sciences to Present New Research Advancing Precision Oncology at the IASLC 2026 World Conference on Lung Cancer | CAI Stock News](https://longbridge.com/en/news/297788849.md)
- [NuCana publishes corporate oncology presentation on ProTide platform](https://longbridge.com/en/news/297702293.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**